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ABSTRACT 47 
Introduction: Few studies have described the prevalence and lung function decline 48 
among those with restrictive spirometric pattern (RSP) in low- and middle-income 49 
countries.  50 
Methods: We analysed prospective data from 2,957 adults recruited across four diverse 51 
settings in Peru over a three-year period. Multivariable logistic regression was used to 52 
study the association between the presence of restriction and associated risk factors. 53 
Multivariable linear mixed models was used to determine lung function decline. 54 
Results: Among 2,957 participants, average age was 55.4 years (SD=12.4) and 49.3% 55 
were male. Overall prevalence of RSP was 4.7% with a range of 2.8% (Lima) to 6.9% 56 
(Tumbes). The odds of having a diagnosis of restriction were higher among those who 57 
lived in a rural environment (OR=2.19; 1.43-3.39), had a diagnosis of diabetes (OR = 58 
1.93, 95% CI 1.10-3.39) and among women (OR=2.09, 95% CI 1.42-2.11). Adjusted for 59 
baseline lung function, adults with RSP had accelerated decline in FEV1 when compared 60 
to non-obstructed, non-restricted individuals. 61 
Discussion: RSP is prevalent particularly among women and in individuals living in rural 62 
settings of Peru. When adjusted for baseline lung function, participants with RSP had 63 
accelerated rates of FEV1 decline. Our findings are consistent with the notion that RSP 64 
is an insidious inflammatory condition with deleterious effects of lung function decline.   65 
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INTRODUCTION  66 
Chronic respiratory disease affects 1 billion people globally and accounts for 7% of all 67 
deaths worldwide 1. The majority of deaths related to chronic respiratory conditions 68 
occur in low- and middle-income countries (LMICs), and the burden of disease is 69 
expected to increase in many LMICs due to rapid urbanization and increased tobacco 70 
consumption 2.  71 
 72 
Over the past decade, population-based, cross-sectional studies have examined 73 
obstructive lung disease among LMICs 3-5. Among these studies, a percentage of 74 
participants were found to have restrictive spirometric values demonstrating reduced 75 
forced vital capacity (FVC) and forced expiratory volume in one second (FEV1) with 76 
preserved overall FEV1/FVC ratio 6-8. Although restriction in spirometry is not restrictive 77 
lung disease, which typically requires measurement of total lung capacity and/or gas 78 
transfer, studies in high-income settings have shown that restrictive spirometric patterns 79 
(RSP) can result in higher risk of morbidity (respiratory symptoms and function status 80 
limitation) as well as all-cause mortality among individuals who present with these 81 
findings 8.  82 
 83 
Global estimates for RSP range from 2.3% in Santiago, Chile to 68% among women in 84 
Mumbai, India, though this variability may be a result of different definitions for RSP and 85 
reference populations 6,7. RSP has been most commonly associated with obesity, 86 
tobacco exposure and female gender in these settings 3,6. In addition, countries with a 87 
high prevalence of biomass cooking fuel use and tuberculosis also had higher 88 
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prevalence of RSP, though potential associations between biomass, tuberculosis and 89 
RSP have not been studied at a household level 4,9.  90 
 91 
While population-based studies have shown varying prevalence of RSP in LMIC 92 
settings, associated morbidity, environmental risk factors and longitudinal health 93 
outcomes among these groups remain poorly defined 6,7. Our primary objective was to 94 
describe the prevalence of and attributable risk factors for RSP across four 95 
geographically diverse settings in Peru. We additionally examine respiratory symptoms 96 
and functional status among those with RSP, and decline in lung function during three 97 
year follow up.  98 
 99 
METHODS 100 
Study Setting  101 
We conducted a longitudinal, population-based study in Peru to determine the 102 
prevalence of chronic pulmonary and cardiovascular diseases across four disparate 103 
regions. This study was described in detail elsewhere 5. Four settings were selected 104 
based on the degree of urbanization and altitude: Pampas de San Juan de Miraflores, 105 
an urbanized community south of Lima; Tumbes, a semi-urban, sea-level community in 106 
northern Peru; Puno, an urban setting 3,825 meters above sea-level; and the rural 107 
communities around Puno 5. 108 
 109 
Study Design  110 
We analysed data from approximately 3,000 adults aged ≥35 years enrolled in a 111 
longitudinal population-based study with annual follow-up from 2010-2013. All subjects 112 
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were randomly selected using a single-stage random selection process and only one 113 
participant per household was enrolled. In Puno, recruitment was stratified to include 114 
500 participants each from the urban and rural settings. Inclusion criteria were age ≥35 115 
years, a full-time resident in the specified setting, and capacity to understand procedures 116 
and consent to the study. Exclusion criteria were pregnancy, physical disability that 117 
prevented measurement of blood pressure or anthropometry, or active pulmonary 118 
tuberculosis. The study was approved by the Institutional Review Boards of Universidad 119 
Peruana Cayetano Heredia and A.B. PRISMA, in Lima, Peru, and the Johns Hopkins 120 
Bloomberg School of Public Health in Baltimore, USA. 121 
 122 
Data collection  123 
Participants responded to a questionnaire on socio-demographics, current smoking 124 
status, respiratory symptoms, past medical history, and family history of non-125 
communicable disease and biomass exposure. Field workers measured weight and 126 
height in triplicate in all three phases. Spirometry was conducted using the Easy-On-PC 127 
spirometer (ndd, Zurich, Switzerland) before and after 200 mcg of inhaled salbutamol via 128 
a spacer following joint American Thoracic Society and European Respiratory Society 129 
(ATS/ERS) guidelines10. Participants with low quality spirometry were asked to repeat 130 
the test on another day for a total of three attempts. Overall 95% met ATS/ERS criteria 131 
including minimum exhalation time of 6 seconds or 12 seconds if no plateau.11  132 
Participants were then invited to follow up annually for three years for repeat spirometry 133 
and phlebotomy. Bronchodilation was conducted at baseline and on the third follow-up 134 
visit 12.  135 
 136 
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Definitions  137 
We defined restrictive spirometric patterns as a pre-bronchodilator FVC below the 5th 138 
percentile (Z score ≤ -1.64) and a post-bronchodilator FEV1/FVC ratio above the 5th 139 
percentile (Z score ≥ -1.64)  of a reference population8, and COPD as a post-140 
bronchodilator FEV1/FVC ratio below the 5th percentile of a reference population. Post-141 
bronchodilator measurements were utilized to exclude individuals with reversible airways 142 
obstruction from a diagnosis of RSP.8 Since there are no established reference 143 
equations for lung function among Peruvians, we utilized the Global Lungs Initiative 144 
(GLI) mixed ethnic reference population. For longitudinal analysis, we included 145 
participants with at least one follow-up visit within the three-year period. 146 
 147 
Biostatistical Methods 148 
For prevalence estimates we included all participants who completed study 149 
questionnaires and had acceptable post-bronchodilator spirometry at baseline. Baseline 150 
risk factors for RSP were analysed using multivariable logistic regression. We evaluated 151 
risk factors for having a diagnosis of RSP including sex, age, urbanization, altitude, daily 152 
smoking, daily use of biomass fuel, history of tuberculosis, chronic bronchitis, hs-CRP, 153 
diabetes, hypertension and body-mass index (BMI). We compared respiratory symptoms 154 
among those with RSP vs. COPD vs. non-restricted, non-obstructed spirometry at 155 
baseline assessing respiratory symptoms. For other analysis we used chi-squared tests 156 
or Fisher’s exact tests to compare proportions, t-tests to compare continuous values, 157 
and Kruskal-Wallis tests to compare categorical values between subgroups as 158 
appropriate.  159 
 160 
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We then built multivariable linear mixed effects models with a random intercept and 161 
random slope by individual to analyse the effect of having RSP at baseline on 162 
longitudinal decline in pre-bronchodilator FEV1 and FVC 13. All models were adjusted for 163 
sex, daily use of biomass fuels, daily tobacco smoking, living in an urban setting, and 164 
living at high altitude. We then used the estimated subject-specific random slopes 165 
divided by baseline lung function to characterize the subject-specific lung function 166 
decline as a percent of baseline forced expiratory volumes. To calculate 95% confidence 167 
intervals for the mean lung function decline as a percent of baseline forced expiratory 168 
volumes, we used the 2.5th and 97.5th percentiles of 3,000 bootstrap resamples by 169 
individual 14. Analyses were performed in R (www.r-project.org) 15-17. 170 
 171 
RESULTS 172 
Participant characteristics  173 
There were 2,957 participants with complete data. We report participant characteristics 174 
in Tables 1 and 2. Those included in analysis had an average age of 55.4 ± 12.4 years, 175 
49% of whom were male. Reported biomass exposure (1%-97%) and tobacco exposure 176 
(<1%-6%) varied between settings. 27.3% of participants had a BMI ≥ 30 kg/m2 (n=833) 177 
and 7% had diabetes (n=207) at baseline. A low percentage of individuals reported a 178 
history of tuberculosis (3%, n=89), with the majority located in Lima (n=72). Across the 179 
sample, 6% of individuals reported symptoms of chronic bronchitis (n=183).  180 
 181 
Prevalence and risk Factors for RSP 182 
The overall prevalence of restriction was 4.6%, with a range of 2.8% (Lima) to 6.9% 183 
(Tumbes) when using the GLI mixed ethnic reference population (Figure 1). Being 184 
8 
 
female was associated with higher odds of RSP (OR=2.09; 95% CI 1.42-2.11) (Figure 185 
2). Similarly, living in a rural area was associated with a higher odds of having RSP 186 
(OR=2.19; 95% CI 1.43 to 3.39) as well as diabetes (OR = 1.93, 95% CI 1.10-3.39). 187 
There was a moderate association of elevated hs-CRP (interquartile OR=1.05; 95% CI 188 
1.00-1.10) and a diagnosis of RSP. Daily smoking, daily use of biomass fuels, site 189 
(urbanization and high altitude), age, BMI, history of tuberculosis, hypertension, and 190 
chronic bronchitis were not by themselves associated with having RSP.  191 
 192 
Respiratory symptoms associated with presence of RSP at baseline 193 
Adults with RSP did not have more respiratory symptoms including cough in the past 12 194 
months (4.5% vs. 4.2%, p=0.87), phlegm in the past 12 months (3.8% vs. 5.7%, p=0.35), 195 
ever wheeze (20.3% vs. 16.7%, p=0.28), difficulty walking/shortness of breath (9.8% vs. 196 
8.3%, p=0.56), hospitalization for respiratory problems in the past 12 months (1.5% vs. 197 
0.4%, p=0.08), and missed work due to respiratory problems in the past 12 months 198 
(3.0% vs. 2.1%, p=0.50) (Figure 3). Mean scores ± SD for the St. George’s Respiratory 199 
Symptoms Questions did not differ between groups among those with RSP compared to 200 
non-restricted, non-obstructed individuals (8.1 ± 15.9 vs. 7.2 ± 12.8). In contrast, adults 201 
with COPD had average scores of 12.9 ± 18.9. Similarly, the modified MRC (mMRC) 202 
Dyspnea Scale scores were not different between RSP and those who were non-203 
restricted and non-obstructed at either baseline (mean mMRC scores 1.17 vs. 1.18; 204 
p=0.72) or at 3-years of follow-up (1.32 vs. 1.26; p=0.31). 205 
 206 
RSP and change in lung function over time 207 
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We report lung function decline both as an absolute value and as a percent of baseline 208 
lung function. There was an inverse relationship between post-bronchodilator FEV1 Z-209 
scores and percent decline in lung function from baseline (Figure 4). Participants with 210 
RSP had a slower absolute rate of lung function decline when compared to non-211 
restricted, non-obstructed individuals (19.2 mL/year vs. 26.6 mL/year, p=0.002); 212 
however, we found that participants with RSP had an accelerated pre-bronchodilator 213 
FEV1 decline when baseline pre-bronchodilator FEV1 was taken into account 214 
(1.15%/year vs. 1.06%/year, respectively; p=0.003) (Table 3).  215 
 216 
DISCUSSION 217 
In this population-based, longitudinal study we describe the prevalence and risk factors 218 
for RSP across four sites with different degrees of urbanization, geography, and altitude 219 
in Peru. Although other studies have examined risk factors for RSP in LMICs, this study 220 
is among the first to assess prevalence and associated risk factors for RSP, and 221 
longitudinal lung function decline. We found overall low rates of RSP particularly in 222 
urban areas. Similarly while living in a rural environment, diabetes, and elevated hs-CRP 223 
were associated with RSP, those exposed to smoking and biomass did not have an 224 
increased risk for RSP. Adjusted for baseline FEV1, participants with RSP had a small 225 
but significant accelerated rate of FEV1 decline when compared to non-restricted, non-226 
obstructed individuals.    227 
 228 
Published data show wide variation in prevalence of RSP among LMICs. In BOLD, the 229 
rates of RSP ranged from 4.2%  to 48.7%, with higher rates of RSP found among LMIC 230 
using fixed-percent predicted cut offs to diagnose RSP 6. Our results were consistent 231 
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with the prevalence of other Latin American countries in PLATINO, which found rates of 232 
RSP ranging from 2.3% to 7%, and used LLN cut-offs as we did 7.  233 
 234 
A number of negative health outcomes among those with RSP have been examined in 235 
longitudinal studies including increased respiratory symptoms, metabolic syndrome, and 236 
mortality 8,18-21. In high-income settings, those with restrictive spirometry patterns have 237 
been shown to have increased burden of respiratory symptoms, when compared to 238 
those with normal spirometry, and perform worse on symptom-based questionnaires.21,22  239 
While our results demonstrate a trend towards greater symptoms among those with RSP 240 
compared to those with normal spirometry, there were no significant differences 241 
between groups as seen with COPD.  242 
 243 
In high-income settings, where obesity is most closely linked to RSP, there is evidence 244 
that RSP may be linked to pro-inflammatory conditions independent of obesity 8,23,24. We 245 
found a diagnosis of diagnosis positively associated with RSP similar to other LMIC-246 
based studies.8 When examining inflammatory biomarkers, studies have demonstrated 247 
elevated levels of hs-CRP among those with lower levels of FVC 24-26. Elevated hs-CRP 248 
was similarly associated with having RSP in Peru. Living in rural settings was also found 249 
to be associated with RSP when controlling for biomass exposure. One explanation for 250 
this may be due to low socioeconomic status among rural groups and lower lung 251 
volumes secondary to malnutrition 27.  252 
 253 
A diagnosis of RSP resulted in accelerated decline in FEV1 as a percentage of baseline 254 
lung function when compared to non-restrictive individuals, non-obstructive individuals in 255 
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longitudinal analysis. Lung function decline had a strong relationship with baseline lung 256 
function across the cohort emphasizing the importance of adjusting estimates of lung 257 
function decline for baseline lung function. While few studies have examined RSP in 258 
LMIC settings, those conducted in high income settings have shown RSP to result in 259 
accelerated absolute lung function decline 8,28. 260 
 261 
A strength of this study is its large population-based sample derived from four diverse 262 
geographical and social settings across Peru. We defined RSP as a pre-bronchodilator 263 
FVC below the LLN, which may explain the lower prevalence of RSP when compared to 264 
earlier studies which used fixed cut-offs. The definition for RSP has varied among 265 
previous studies and have included FVC  <80%, FVC <LLN and FEV1 <80% 8. A 266 
definition including both FEV1 and FVC may further identify phenotypes at risk for 267 
negative health outcomes. Limitations in this study include a short follow up time of three 268 
years. The high prevalence of biomass use in rural areas vs low utilization in urban 269 
areas additionally made these variables difficult to interpret separately.  270 
 271 
Ultimately, the Peruvian population with RSP included in this study differed in both 272 
respiratory symptoms and showed small but significantly increased lung function decline 273 
compared to non-restricted, non-obstructed individuals, which raises the question of 274 
whether RSP is a diagnosis which confers risk for negative health outcomes. We did find 275 
elevated hs-CRP among those with RSP, independent of obesity and other comorbid 276 
conditions, indicating that a similar inflammatory pattern found in high-income settings 277 
may apply to those with RSP in low-income settings. In many LMIC settings, diagnostic 278 
equipment for assessing restriction is prohibitive, requiring high expense, a steady 279 
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supply of mixed-gas, and skilled technicians. While a diagnosis of RSP does not 280 
necessitate restriction, it may prove a valuable proxy for systemic inflammatory disease 281 
processes which warrant further analysis particularly in LMIC settings.  282 
 283 
Conclusions 284 
This multi-site population-based study showed that RSP was prevalent in Peru and 285 
being female, diagnosis of diabetes and living in a rural environment were associated 286 
with increased odds of having lower forced vital capacity with a high normal or preserved 287 
FEV1/FVC ratio. Those with RSP had accelerated lung function decline when compared 288 
to non-restricted, non-obstructed individuals. This is consistent with previous findings, 289 
whereby RSP is hypothesized to be an insidious inflammatory process with deleterious, 290 
measurable effects of lung function decline.  291 
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Table 1. Sociodemographic and disease characteristics by site 370 
 371 
 
 
Tumbes 
Rural 
Puno 
Urban 
Puno 
Lima 
Age in years, mean (SD) 
56.1 
(13.3) 
55.8 
(12.6) 
55.4 (12.2) 
55.1 
(11.8) 
RSP positive when using GLI 
Mixed Ethnic reference 
population, % (n) 
6.9 (68) 5.1 (27)  3.7 (19) 2.8 (28) 
      
Percentage of Males (n) 50 (498) 48 (253) 49 (255) 49 (496) 
Chronic bronchitis, % (n) 2 (15) 8 (39) 7 (35) 9 (94) 
Use biomass daily, % (n) 23 (229) 97 (484) 1 (25) 6 (63) 
BMI ≥ 30 kg/m2, % (n) 32 (312) 10 (55) 27 (139)  32 (327) 
Daily smokers, % (n)  6 (56)  0 (1) 2 (11) 3 (33) 
Diabetes, % (n) 10 (102) 3 (16) 7 (34) 6 (55) 
hs-CRP, mean (SD) 4.0 (6.7) 2.5 (9.6) 2.8 (5.1) 3.6 (5.9) 
Tuberculosis, % (n) 1 (7) 1 (7) 1 (3) 7 (72) 
Wealth index, % (n)     
 Lowest 33 (324) 71 (373) 24 (122) 12 (123) 
 Middle 41 (401) 26 (140)    26 (132) 37 (375) 
 Highest 26 (263) 3 (15) 50 (262) 51 (516) 
 372 
  373 
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Table 2. Baseline sociodemographic and Disease Characteristics of RSP vs. Non-374 
obstructed, Non-restricted and COPD using GLI Mixed Ethnic reference population. 375 
 RSP Non obstructed or restricted COPD 
Age in years, mean (SD)  55.7 (13.0) 55.2 (12.3) 58.4 (13.9) 
Number of Males (%) 43 (32.3) 1296 (49.1) 118 (63.4) 
Use biomass daily, n (%) 39 (29.3) 681 (25.9) 70 (37.6) 
BMI ≥ 30 kg/m2, n (%) 38 (28.6) 740 (28.1) 32 (17.3) 
Daily smokers, n (%) 5 (3.8) 87 (3.3) 5 (2.7) 
Diabetes, n (%) 17 (12.8) 173 (6.7) 4 (2.2) 
hs-CRP, mean (SD) 4.8 (9.4) 3.3 (6.5) 4.3 (8.2) 
Tuberculosis, n (%) 4 (3.0) 62 (2.9) 20 (10.8) 
Wealth index, n (%)    
 Lowest 48 (36.1) 780 (29.6) 74 (39.8) 
 Middle 47 (35.3) 906 (34.4) 65 (34.9) 
 Highest 38 (28.6) 948 (36.0) 47 (25.3) 
Pre-bronchodilator 
spirometry Z scores 
   
 FVC, mean (SD) -1.53 (1.25) 1.05 (1.24) 0.70 (1.6) 
 FEV1, mean (SD) -1.50 (1.12) 0.76 (1.14) -0.76 (1.4) 
 FEV1/FVC, mean (SD) -0.16 (1.32) -0.41 (0.84) -2.2 (0.95) 
Post-bronchodilator 
spirometry Z scores 
   
 FVC, mean (SD) -1.18 (1.20) 1.32 (1.21) 1.0 (1.6) 
 FEV1, mean (SD) -1.01 (1.08) 1.12 (1.16) -0.29 (1.4) 
 FEV1/FVC, mean (SD) 0.25 (1.07) 0.02 (0.76) -1.95 (0.80) 
 376 
 377 
 378 
 379 
 380 
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Table 3: Average change per year in lung function (mL/year) and percentage change from baseline adjusted for sex, 
biomass exposure, tobacco exposure, urbanization and high altitude compared to non-restricted, non-obstructed 
individuals stratified by reference population used for diagnosis of RSP.  
 
 
 Non-restricted, non-obstructed 
 
Restrictive spirometric pattern 
 FEV1 (95% CI) FVC (95% CI) FEV1 (95% CI) FVC (95% CI) 
Estimated lung function 
decline (ml/year)  
26.6 (25.6, 27.7) 28.7 (27.3, 30.1) 19.2 (14.7, 23.6) 22.2 (16.5, 27.9) 
Estimated lung function 
decline as a percentage 
of baseline forced 
expiratory volume (%/yr)  
1.06% (1.04%, 1.07%) 0.89% (0.88%, 0.90%) 1.15% (1.10%, 1.22%) 1.06% (1.01%, 1.12%) 
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Figure 1: Prevalence of RSP by age category, stratified by sex. 
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Figure 2: Odds Ratio of having RSP for rural environment vs. urban, women vs. men, 
living at high altitude (3800m) vs. low altitude (sea level), diabetes vs. no diabetes, hs-
CRP (75th vs 25th percentile), daily biomass exposure vs non-daily, and daily smoking vs 
non-daily, stratified by sex. 
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Figure 3: Prevalence of negative health outcomes and respiratory symptoms (missed 
work days because of respiratory problems in the last 12 months, hospitalization for 
respiratory problems in the last 12 months, dyspnea on exertion, ever wheeze, phlegm, 
and cough in last 12 months) between groups (RSP vs. Non-restricted, non-obstructed 
vs. COPD). 
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Figure 4: Baseline pre-bronchodilator Z scores vs change in lung function as a 
percentage of baseline, stratified by FEV1 and FVC. Longitudinal models were adjusted 
for sex, biomass exposure, tobacco exposure, urbanization and altitude. Data was 
grouped by baseline Z-score (20 bins for FEV1 and 21 bins for FVC). The mean values for 
lung function decline (with error bars showing ± one standard deviation) were plotted in 
black, with the non-binned values plotted in grey.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
